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Abstract
Heart rate variability is an important risk factor for cardiovascular disease and all-cause mortality. The acetylcholine pathway plays a
key role in explaining heart rate variability in humans. We assessed whether 443 genotyped and imputed common genetic variants
in eight key genes (CHAT, SLC18A3, SLC5A7, CHRNB4, CHRNA3, CHRNA, CHRM2 and ACHE) of the acetylcholine pathway were
associated with variation in an established measure of heart rate variability reflecting parasympathetic control of the heart rhythm,
the root mean square of successive differences (RMSSD) of normal RR intervals. The association was studied in a two stage design
in individuals of European descent. First, analyses were performed in a discovery sample of four cohorts (n = 3429, discovery stage).
Second, findings were replicated in three independent cohorts (n = 3311, replication stage), and finally the two stages were
combined in a meta-analysis (n = 6740). RMSSD data were obtained under resting conditions. After correction for multiple testing,
none of the SNPs showed an association with RMSSD. In conclusion, no common genetic variants for heart rate variability were
identified in the largest and most comprehensive candidate gene study on the acetylcholine pathway to date. Future gene finding
efforts for RMSSD may want to focus on hypothesis free approaches such as the genome-wide association study.
Citation: Riese H, Muñoz LM, Hartman CA, Ding X, Su S, et al. (2014) Identifying Genetic Variants for Heart Rate Variability in the Acetylcholine Pathway. PLoS
ONE 9(11): e112476. doi:10.1371/journal.pone.0112476
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Genes for Heart Rate Variability

adults. The ACHE, CHAT, and SLC18A13 genes have been
investigated as functional candidates for Alzheimer’s disease
[14,15]. The fact that patients with Alzheimer’s disease have
reduced HRV [16,17] and this autonomic dysfunction can be
normalized by acetylcholinesterase inhibitor treatment [16]
suggests that these three genes are also candidate genes for
HRV. SLC18A3 lies within the first intron of CHAT [18].
The genes for the b4, a3, and a5 subunits of nicotinic receptors
(CHRNB4, CHRNA3, and CHRNA5) are clustered on chromosome 15q24 and physically linked [19]. Interestingly, the only
genome-wide linkage scan conducted so far for HRV [20] yielded
a multipoint LOD score of 1.84 on chromosome 15 close to this
gene cluster. Among the five subtypes of muscarinic receptors
(M1-M5), the mammalian heart predominantly expresses M2
receptors [21]. In CHRM2 knockout mice, bradycardia caused by
vagal stimulation was completely abolished [22].
In the current study, we assessed whether common genetic
variants in these eight key genes of the acetylcholine pathway were
associated with RMSSD in a total of 3429 individuals of European
descent from four cohorts. Findings were replicated in 3155
subjects from three further cohorts of European descent. The key
objective of this study was to identify genetic variants in the
acetylcholine pathway contributing to variation in RMSSD.

Introduction
Heart rate variability (HRV) is the variation over time of the
interval between consecutive heart beats. HRV in the respiratory
frequency range is a specific marker of parasympathetic control of
the heart rhythm [1], and can be reliably assessed by the root
mean square of successive differences (RMSSD) of normal RR
intervals [2]. Prior research has produced an extensive list of HRV
correlates including a broad range of somatic and mental health
problems [3]. High HRV is a sign of good adaptability, often used
as a marker of well-functioning cardiac autonomic control
mechanisms. Reduced HRV is a predictor of hypertension [4],
all-cause mortality, arrhythmic events, and sudden death after
acute myocardial infarction as well as in the general population
[4–7].
The parasympathetic (vagal) branch of the autonomic nervous
system has an inhibitory influence on the pace-making activity of
the sinoatrial node of the heart. Parasympathetic regulation of the
heart is mediated by acetylcholine neurotransmission. Acetylcholine activates mainly two types of receptors, the muscarinic and
nicotinic receptors. Muscarinic receptors are found on all effector
cells that are stimulated by the postganglionic cholinergic neurons
of the parasympathetic nervous system. Nicotinic receptors are
found on the postganglionic neurons of the autonomic ganglia.
The two types of receptors have different functions, and specific
drugs can be used to stimulate or block one or the other type [8].
Although there is consistent evidence for the influence of genetic
factors on HRV from twin studies showing heritabilities up to 51%
[9–11], very few studies have tried to identify the genetic
polymorphisms responsible for this heritability [12]. Genes
involved in the regulatory pathways of acetylcholine, the
neurotransmitter of the parasympathetic nervous system, seem
plausible candidates to harbor such polymorphisms. In the present
study we examined eight key genes (listed in Table 1) involved in
biosynthesis, transport, breakdown, and receptor binding of
acetylcholine. With the exception of the choline transporter [13],
these genes have not been investigated in genetic studies of HRV
before.
Neumann et al. [13] genotyped one single nucleotide polymorphism (SNP, rs3731683) in SLC5A7, and observed that this
polymorphism was significantly associated with HRV in 413 white

Methods
Subjects
For the discovery stage, we included subjects from four cohorts:
the Georgia cohort (GA) [23], the TRacking Adolescents’
Individual Lives Survey population cohort (TRAILS-P) [24], the
Twin Interdisciplinary Neuroticism Study (TWINS) [25], and the
Netherlands Study of Depression and Anxiety (NESDA) cohort
[26]. As replication samples The Prevention of Renal and
Vascular End-stage Disease study (PREVEND) [27], the TRacking Adolescents’ Individual Lives Survey clinical cohort (TRAILSCC) [24], and the Netherlands Twin Registry (NTR) [28] were
used. A short description of the different cohorts is given below;
the general characteristics are listed in Table 2. The study
protocol was approved by the Research Ethics Board at The
Institutional Review Board at the Medical College of Georgia,

Table 1. Eight key genes involved in synthesis, metabolism and receptor binding of acetylcholine.

Protein

Gene

Chr

Physical position (bp)*

Genotyped tSNPs**

Imputed SNPs

Acetylcholinesterase

ACHE

7

100,487,615–100,494,594

4/4/1

3/3/6

Choline transporter

SLC5A7

2

108,602,979–108,630,450

12/12/16

43/43/39

Choline acetyltransferase

CHAT

10

50,817,141–50,901,925

26/29/19

63/60/70

Vesicular acetylcholine
transporter

SLC18A3

10

50,818,347–50,820,765

Nicotinic receptors a3 subunit

CHRNA3

15

78,885,394–78,913,637

10/9/10

66/67/66

Nicotinic receptors a5 subunit

CHRNA5

15

78,857,862–78,887,611

Nicotinic receptors b4 subunit

CHRNB4

15

78,916,461–79,020,096

Muscarinic receptor 2

CHRM2

7

136,553,416–136,705,002

35/36***/45

181/180/171

Note: Chr, chromosome.bp, base pair;
*Physical position is based on NCBI build 35;
**GA/(TRAILS-P & TWINS)/NESDA, as TRAILS-P and TWINS were jointly genotyped the middle number represents genotyped SNPs of both cohorts. See the method
section for further details;
***One tSNP was replaced with two substitutes during the assay design stage. All imputed SNPs had at least an imputation quality (Info score) of 0.5. See the methods
section for further details.
doi:10.1371/journal.pone.0112476.t001
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Means and SD are given unless indicated otherwise.
Note: details on the different cohorts are given in the method section.
doi:10.1371/journal.pone.0112476.t002

61.02634.41

4.1163.54
4.3060.63

88.77654.26
29.35619.70

3.2360.51
3.5160.60

39.9625.8

USA (GA), Central Committee on Research Involving Human
Subjects (CCMO; TRAILS-P, TRAILS-CC), Medical Ethics
Committee of the University Medical Center Groningen, Groningen (TWINS, PREVEND), and the Ethical Review Board of the
VU University Medical Center (NTR, NESDA). Participants were
treated in accordance with the guidelines of the declaration of
Helsinki, and all measurements were carried out with their
adequate understanding and written consent provided by all
subjects and by parents if subjects were ,18 years.
The GA cohort included subjects from two studies: the BP
Stress Study and the Georgia Cardiovascular Twin Study. Both
are ongoing longitudinal studies, which have followed the subjects
more than 10 years including roughly equal numbers of
Caucasians and African Americans and men and women. The
BP Stress Study was established in 1989 with subjects aged 7–16
years at baseline [29], while the Georgia Cardiovascular Twin
Study was established in 1996 with subjects aged 7–25 years at
baseline [30]. For the twin study, the twin pairs were reared
together and zygosity was determined using five standard
microsatellite markers. Subjects in both studies were recruited
from the southeastern United States and were overtly healthy and
free of any acute or chronic illness based on parental report. Study
design, selection criteria and the criteria to classify subjects as
Caucasians or African Americans for these two studies have been
described before [31,32]. A total of 682 Caucasians were available
for this study of which i) 261 subjects (mean6SD age, 23.162.88
years; range, 15.6 to 31.8 years) from the BP stress cohort who had
RMSSD measured on visit 13 and, ii) 421 twins (mean6SD age,
17.963.95 years; range, 11.9 to 32.9 years; 45 singletons and 188
twin pairs) from the Georgia Cardiovascular Twin Study who had
RMSSD data available from the third visit.
The TRAILS-P cohort included subjects from the ongoing
longitudinal population cohort, which started in 2001. Sample
selection procedures and methods of study have been described
before [24,33,34]. For the current study, data of 1029 10-to-13year-old Dutch preadolescents (47.6% boys, mean6SD age,
11.560.53 years) were used for whom RMSSD data were
available from the first measurement wave. A more detailed
description of the group that participated in the cardiovascular
measurements has been given elsewhere [35].
The TWINS cohort was drawn from the Groningen Twin
Register, a 3-wave study including approximately 800 twin pairs
from the Northern part of the Netherlands [25]. At the second
wave a selection of 125 female twin pairs between 18 and 30 years
old were invited to visit a psychophysiological laboratory to
perform various rest and mental stress tasks. For the current study,
valid RMSSD data of 216 subjects were available [11]. Zygosity of
this target group was determined using 10 microsatellite markers.
The NESDA cohort was drawn from a larger 8-year
longitudinal study conducted among 652 persons without depression or anxiety disorder and 2329 with a remitted or current
diagnosis of depression or an anxiety disorder [26]. For the current
study, 1502 NESDA subjects were included from which RMSSD
data were collected on the baseline measurement session of the
study and who had been genotyped on a genome-wide platform.
The PREVEND cohort was drawn from a larger communitybased prospective cohort which was originally initiated to
investigate the natural course of increased albuminuria levels
and its association to renal and cardiovascular disease [27,36].
PREVEND subjects completed the baseline survey from 1997 to
1998. At the second screening (2001 to 2003) RMSSD data were
obtained from 2793 subjects.
The TRAILS-CC cohort included subjects from the ongoing
longitudinal cohort of clinically referred subjects following the

3.4960.58

39.0626.3
73.8638.6

4.1660.55

RMSSD (ms)

log RMSSD

75.5649.9

19.964.4

4.1060.69

31.2

30.83614.42
11.1160.48
53.21611.67
41.6612.4
23.263.5

211

Age (years)

11.560.53

69.3

307
2793

50.5
31.4

1502
216

0
47.6
50.6
Men, %

TWINS
TRAILS-P

1029
682
N

TRAILS-CC
PREVEND
GA

NESDA

Replication Cohorts
Discovery Cohorts

Table 2. General characteristics of the subjects included in the study of the four discovery cohorts and the three replication cohorts.
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rs324576

CHRM2

CHRM2

CHRM2

7

8

9

rs17269293

4

rs333230

rs324612

19 SLC5A7

20 CHRM2

rs12356649

rs12358003

24 CHAT

25 CHAT

G/C

A/G

G/A

A/G

G/A

T/C

G/T

G/A

C/T

G/A

G/A

A/G

T/A

T/C

G/A

A/T

T/C

T/C

T/A

T/C

C/G

T/C

T/C

A/G

G/A

C/NC

0.85

0.85

0.08

0.08

0.15

0.08

0.15

0.15

0.08

0.08

0.08

0.85

0.08

0.08

0.08

0.08

0.08

0.49

0.49

0.07

0.82

0.43

0.47

0.88

0.66

20.041

20.041

20.054

20.054

20.041

20.055

20.041

20.041

20.056

20.056

20.056

20.044

20.057

20.058

20.058

20.058

20.058

20.031

20.032

20.066

20.043

20.035

20.035

20.061

20.052

CAF Beta

Discovery

0.021

0.021

0.027

0.027

0.020

0.027

0.020

0.020

0.027

0.027

0.027

0.021

0.027

0.027

0.027

0.027

0.027

0.014

0.014

0.029

0.018

0.015

0.014

0.022

0.016

SE

0.048

0.048

0.047

0.046

0.044

0.043

0.042

0.041

0.041

0.039

0.038

0.035

0.034

0.034

0.034

0.033

0.032

0.029

0.024

0.022

0.021

0.017

0.014

0.005

0.002

Pvalue

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

75.9

0

0

18.4

14.9

I2 (%)

0.91

0.91

0.69

0.69

0.48

0.65

0.56

0.56

0.57

0.65

0.61

0.92

0.62

0.61

0.62

0.62

0.62

0.92

0.89

0.66

0.01

0.76

0.97

0.30

0.32

PvalueQ
statistic

0.84

0.85

0.07

0.06

0.16

0.08

0.15

0.16

0.06

0.08

0.08

0.85

0.08

0.08

0.08

0.07

0.08

0.47

0.47

0.08

0.79

0.41

0.47

0.87

0.67

0.005

20.003

0.021

0.049

20.005

0.027

0.001

20.003

0.040

0.012

0.012

20.003

0.012

0.012

0.012

0.098

0.012

20.009

20.009

0.018

0.018

20.007

20.008

0.031

0.048

CAF Beta

Replication

0.858

0.031

0.017

0.026

0.043

0.017

0.026

0.886

0.852

0.424

0.253

0.768

0.313

0.981

0.017
0.019

0.357

0.581

0.582

0.848

0.591

0.582

0.582

0.077

0.600

0.461

0.473

0.426

0.436

0.591

0.511

0.583

0.044

P value

0.044

0.022

0.022

0.017

0.022

0.022

0.022

0.056

0.021

0.012

0.013

0.023

0.023

0.014

0.012

0.057

0.024

SE

0

0

0

0

11.7

0

50.9

49.8

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

37.9

0

I2 (%)

0.59

0.57

0.83

0.97

0.32

0.86

0.13

0.14

0.97

0.75

0.75

0.52

0.70

0.76

0.76

0.47

0.83

0.42

0.38

0.94

0.83

0.40

0.48

0.20

0.48

Pvalue Q
statistic

20.027

20.019

20.015

20.025

20.020

20.130

20.019

20.019

20.029

20.015

20.015

20.020

20.016

20.015

20.015

20.028

20.016

20.019

20.019

20.015

20.019

20.020

20.020

20.049

20.020

Beta

0.017

0.013

0.019

0.023

0.013

0.019

0.014

0.013

0.023

0.017

0.017

0.013

0.017

0.017

0.017

0.025

0.017

0.010

0.010

0.018

0.015

0.010

0.010

0.020

0.013

SE

0.117

0.159

0.426

0.280

0.131

0.490

0.172

0.148

0.214

0.389

0.382

0.137

0.350

0.368

0.367

0.255

0.352

0.047

0.042

0.417

0.185

0.044

0.034

0.016

0.144

Pvalue

Overall meta-analysis

32.4

49

74.8

75.7

45.9

78.5

56.2

53

71.3

73.8

74

56.2

74.4

75

75.1

84.3

74.9

27.7

31.9

80.9

76

47.7

50.1

56.6

91.6

I2 (%)

0.22

0.16

0.05

0.04

0.17

0.03

0.13

0.15

0.06

0.05

0.05

0.13

0.05

0.05

0.05

0.01

0.05

0.24

0.23

0.02

0.04

0.17

0.16

0.13

0.001

Pvalue Q
statistic

SNPs are sorted according to p-value in the discovery cohort.
Note: RMSSD was log-transformed prior data analysis. Analyses are age & sex adjusted. Discovery stage sample size (N) = 3429; Replication stage N = 3311(except for one SNP [rs333214] in the SLC5A7 gene where N = 516, because
this SNP could not be analyzed in PREVEND due to low imputation quality); and overall meta-analysis N = 6740. See the methods section for further details on the imputation procedures for the different cohorts. C/NC, coded/noncoded allele; CAF, coded allele frequency.
doi:10.1371/journal.pone.0112476.t003

rs324624

rs324627

22 CHRM2

23 CHRM2

rs333226

rs333227

18 SLC5A7

21 SLC5A7

rs324584

rs324632

16 CHRM2

17 CHRM2

rs10508915

rs324582

14 CHAT

15 CHRM2

rs324580

rs324587

12 CHRM2

13 CHRM2

rs324578

rs324579

10 CHRM2

11 CHRM2

rs10246819

rs6962027

rs324654

SLC5A7

CHRM2

5

rs6967953

rs17506824

rs333214

rs3731683

SNP

6

CHRM2

CHRM2

3

4

SLC5A7

SLC5A7

1

2

Gene

Table 3. Results of discovery stage, replication stage and the overall meta-analysis of the 25 SNPs associated with RMSSD (p,0.05) in the discovery stage.
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In the NESDA cohort RMSSD was computed on the ECGderived RR interval time series measured with the Vrije
Universiteit Ambulatory Monitoring System (VU-AMS) [45,46].
Subjects wore the VU-AMS device during a large part of the
baseline assessment while participating in other assessments
(medical examination, an interview and a computer task). Further
details on the assessment have been described before [47].
In the PREVEND cohort RMSSD was computed on the RR
interval time series based on the beat-to-beat blood pressure
signals measured with the Portapres device (FMS Finapres
Medical systems BV, Amsterdam, The Netherlands; [48]).
Subjects were measured in the supine resting condition, after
resting for five minutes, during 15 minutes, while holding their
hand with the Portapres cuff at heart level. They were not allowed
to talk or to move during the measurement. In short, from the
15 minute recording an artifact free period of at least 100 seconds
but no longer than five minutes was selected for RMSSD
calculations. The same data cleaning procedure as described
above for the TRAILS-P, TRAILS-CC, and TWINS studies was
used. Further details have been described before [49].
In the NTR cohort RMSSD was computed on the ECGderived RR interval time series measured with the VU-AMS
device during a 24-h ambulatory monitoring procedure which has
been described before [38,39]. Prompted by the VU-AMS device,
the subjects filled out a diary every 30 (610) minutes in which they
logged their physical activities and bodily postures since the
previous prompt. This diary information was combined with
simultaneously recorded vertical accelerometer data to divide the
entire 24-h recording into periods of homogeneous activities/
postures (median duration 26.2 minutes). From the total set of
ambulatory RMSSD measurements only the evening measurements were selected where subjects were seated calmly for at least
five minutes but no longer than 60 minutes. The average of these
measurements was taken as their RMSSD resting value.

same protocol as the TRAILS-P cohort described above. Sample
selection procedures and methods of study have been described
before [24,33,37]. For the current study data of 307 TRAILS-CC
10-to-12-year-old Dutch preadolescents (69.3% boys, mean6SD
age, 11.1160.48 years) were used for whom RMSSD data were
obtained at the first measurement wave.
The NTR cohort that was established in the late 1980s,
consisted of Dutch adult twins (mean age 6SD, 30.83614.42
years) that had participated in one of various studies of
cardiovascular regulation [38,39] and had been part of the GAIN
genotyping effort [40]. RMSSD data obtained during a resting
condition were used.
In all cohorts subjects with heart disease and those taking
antidepressant or anticholinergic medications were excluded from
the analyses.

Heart rate variability measurement and processing
For the GA cohorts, the continuous RR intervals were recorded
with BioZ (CardioDynamics, San Diego, CA) impedance monitors. Four dual sensors connected to the BioZ were placed on the
subject’s neck and thorax, which formed four electrocardiogram
(ECG) vectors. These ECG vectors can be detected by the BioZ.
The BioZ then converted the RR interval into beat-to-beat heart
rate with a precision of 2 decimal places, including a record of the
real time of each beat. At the 10th, 12th, and 14th minute of the
15-minute resting period, a 30-second continuous period of RR
intervals was recorded. Prior to calculation of HRV parameters,
the raw RR interval data were firstly processed for artificial
readings using the following two criteria: (1) RR intervals were
between 300 and 2000 ms; (2) the successive RR interval ratios
were between 0.8 and 1.2. Dedicated HRV software (Kubios
HRV analysis) [41] was used to compute the RMSSD from the
RR intervals. RMSSD was calculated as the average of the three
30-second segments of continuous RR intervals.
In the TRAILS-P and TRAILS-CC cohorts, RMSSD was
computed on the ECG-derived RR interval time series. ECG
measurements took place in a quiet room at school (TRAILS-P) or
at the hospital research center (TRAILS-CC). First, subjects lied
down and were encouraged to relax and not to move or speak.
Next, the procedure was explained to them and data acquisition
did not commence until the signal was considerably stable (i.e., as
visually observed through the levelling out of the signals after
initial fluctuations), usually within five minutes. RR intervals were
registered for four minutes in the supine position. To obtain RR
intervals with sufficient resolution for HRV determination, a
special interpolation algorithm was used, increasing the time
resolution for R-peak detection by a factor of 2.5. After initial
visual inspection and exclusion of unusable signals, stationarity of
the time series was checked and artifacts were corrected using the
CARSPAN program (IECProgamma, Rijks Universiteit Groningen, Groningen, The Netherlands) [42]. A more detailed
description of cardiovascular data assessment, analysis, attrition,
and internal reliability has been given before [35].
In the TWINS cohort RMSSD was computed on the ECGderived RR interval time series, which were assessed in a quiet
laboratory with a three-lead ECG during four standardized
conditions: a rest condition, two stress conditions, and a second
rest condition. Cardiovascular measurements started after the
subjects had relaxed in sitting position for at least 10 minutes.
Each condition lasted for about five minutes. The average of the
two rest conditions was used in the current study. The same data
cleaning procedure as described above for the TRAILS-P and
TRAILS-CC studies was used. Further details have been
described before [43,44].
PLOS ONE | www.plosone.org

SNP selection
For the GA cohorts, tagging SNPs were selected from HapMap
phase II data (July, 2007) for seven genes including CHAT,
SLC18A3, SLC5A7, CHRNB4, CHRNA3, CHRNA5 and
CHRM2 using Haploview pairwise tagging with a r2$0.8. All
the common SNPs with a minor allele frequency (MAF) $5%
within the gene as well as 210 kb upstream and +10 kb
downstream of the gene were covered. Since the HapMap had a
limited number of SNPs available in the ACHE gene at the time
when tagging SNPs were selected (July, 2007), the SNP data from
the SeattleSNPs Variation Discovery Resource (www.pga.gs.
washington.edu), which had completely re-sequenced ACHE in
23 white Americans, was used for tagging SNPs selection. Table 1
lists the physical position, number of the tagging SNPs selected,
the genotyped and imputed SNPs for the eight key genes. Since
SLC18A3 is within the first intron of the CHAT gene and
CHRNB4, CHRNA3, and CHRNA5 are within one gene cluster,
these genes were listed together as two loci in Table 1.
For the TRAILS-P, TRAILS-CC and TWINS cohorts, the
same tagging SNPs as selected for the Caucasian GA cohorts
described above were selected. For the NESDA cohort, which had
genome wide genotyping data, SNPs within the same physical
regions were selected for this study.

DNA extraction and genotyping
In the GA cohorts, genotyping of blood derived DNA was
performed by BioServe Biotechnologies (Laurel, MD) using
Sequenom’s high-throughput matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry. All
5
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genotyping results were reviewed manually for quality control.
Two ‘no template’ controls and two positive controls were
included on each plate. In addition, 107 sets of blinded controls
were distributed throughout the plates for quality control
purposes. There was excellent observer agreement in the
randomly selected duplicates that were included for quality control
purposes. The kappa statistic ranged from 0.89 to 1, with an
average of 0.974.
In a subsample of the TRAILS-P, TRAILS-CC and TWINS
cohorts, DNA was extracted from blood samples or (in a few cases)
buccal swabs (Cytobrush) using a manual salting out procedure
[50]. Genotyping was performed on the Golden Gate Illumina
BeadStation 500 platform (Illumina Inc., San Diego, CA, USA),
following the manufacturers protocol. Genotyping data and
clustering was performed in BeadStudio 3.0 (Illumina Inc., San
Diego, CA, USA). Concordance between DNA replicates showed
a genotyping accuracy of 100%. Data cleaning was in line with
standard procedures [51]. The call rate in the combined set of
TRAILS-P, TRAILS-CC, and TWINS after data cleaning was
99.8%. In addition to this candidate gene genotyping, genomewide genotyping of TRAILS-CC was performed using the
Illumina HumanCytoSNP12 v2 beadchip assay (Illumina, Inc;
San Diego, CA, USA). Genotypes were called with the Illumina
GenomeStudio software package (Illumina, Inc). Details on
genotyping and quality control have been given elsewhere [52].
In the NESDA and NTR cohorts, genome-wide genotyping of a
subsample of the subjects was performed as part of the GAIN
initiative to detect genetic variation associated with major
depression [40]. Genotyping was performed on Affymetrix
500 K GeneChip arrays. A detailed description of genotyping
and quality control criteria has been given previously [53].
For PREVEND genome-wide genotyping of a subsample of the
cohort was performed using the Illumina HumanCytoSNP12 v2
beadchip assay (Illumina, Inc; San Diego, CA, USA). Genotypes
were called with the Illumina GenomeStudio software package
(Illumina, Inc). Details on genotyping and quality control have
been described before [54].

same time the kappa statistic for the randomly selected duplicates
on the genotype of these SNPs was less than 0.90. For the
TRAILS-P and TWINS cohorts, SNPs were excluded if they
violated HWE (p,0.01). For the NESDA, NTR, PREVEND, and
TRAILS-CC cohorts SNPs with a HWE p-value below1025 were
excluded.
The genotyped and imputed SNPs were examined for their
associations with RMSSD under an additive model of inheritance
with adjustment for age and sex. For imputed SNPs dosages were
calculated and used in the analyses to properly account for
uncertainty in the imputed genotypes. RMSSD was log-transformed in the analyses. For the GA and TWINS cohorts,
generalized estimating equations were used with exchangeable
correlation structure to account for familial correlations. A fixed
effects meta-analysis on these four cohorts was conducted using the
inverse variance weighted method. The Q and I2 statistics were
used to estimate between study heterogeneity. To help interpret
I2’s magnitude we used guidelines from Higgins and colleagues
[58] in which I2#25% marks low, I2 = 50% medium, and I2$75%
high heterogeneity.
To optimize the chances of discovery we used a relatively
lenient p,0.05 cut-off in the discovery stage. That is, all SNPs
with p,0.05 in the discovery stage were taken forward for
replication in three independent samples: PREVEND, TRAILSCC and NTR. For all three replication cohorts results for these
SNPs were extracted from genome-wide analyses of log-transformed RMSSD, who analyzed it by means of SNPTEST [55]
using an additive model with age and sex as covariates and taking
the uncertainty in the imputed genotypes into account. Results
from discovery and replication phase were subsequently combined
in a meta-analysis using METAL [59]. When not mentioned
analyses were performed in StataSE software (version 12,
StataCorp, College Station, Texas, USA).

Results
The characteristics of the subjects included in the analysis in
each of the cohorts are given in Table 2. Of the 95 SNPs selected
in the design stage, 87 were successfully genotyped in the GA
cohort and 90 in the TRAILS-P and TWINS cohorts (Table 1).
No further SNPs were excluded as all met our criteria for inclusion
(see methods). All imputed SNPs in the discovery cohorts had at
least an imputation quality (info score) of 0.5. In total, 443
genotyped and imputed SNPs were included in the association
analysis with RMSSD.

Imputation
Non-genotyped SNPs within the eight genes, as well as 210 kb
upstream and +10 kb downstream of the genes, were imputed. For
the GA, TRAILS-P and TWINS cohorts, for seven genes (CHAT,
SLC18A3, SLC5A7, CHRNB4, CHRNA3, CHRNA5 and
CHRM2), imputation was performed using Phase II CEU
HapMap data (release 24, build 36) as the reference database
using IMPUTE version 0.3.2[55], while for the ACHE gene,
imputation was performed using Phase III CEU HapMap data
(release 2, build 36) because coverage of this gene in HapMap
Phase II (release 24) was minimal. For the NESDA cohort
imputation was done with IMPUTE version 2.1.2 [56] using the
ALL panel of the 1000 Genomes phase I integrated variant set of
March 2012. For the NTR and TRAILS-CC cohorts imputation
was done with IMPUTE version 0.3.2 [55] using Phase II CEU
HapMap data (release 22, build 36) reference population. For the
PREVEND cohort imputation was done with Beagle version 3.1.0
[57] using the Phase II CEU HapMap (release 23a, build 36)
reference population.

In the discovery phase the association between the candidate
SNPs and RMSSD were tested in four cohorts (n = 3429; GA,
TRAILS-P, TWINS and NESDA). For 25 SNPs an association
with RMSSD (p,0.05) was found (see Table 3).
When testing the genetic heterogeneity of the SNPs in this
phase, the point estimate for I2 was significant for only one SNP
(rs17269293; I2 = 75.8%). Heterogeneity for all other SNPs was
either completely absent or low and non-significant, confirming
that performing a fixed effects meta-analysis on these data is
justified (Table 3).

Statistical analysis

Replication stage and the overall meta-analysis

Hardy-Weinberg equilibrium (HWE) was tested in each cohort
by a x2 test with 1 df. To prevent inflated significance, these tests
were performed in data including only one of the twins, chosen at
random, in the GA and TWINS cohorts. For the GA cohort,
SNPs were excluded if they violated HWE (p,0.01) and at the

To validate the association found in the discovery phase, the 25
lead SNPs (Table 3), were taken forward to the replication phase
in three independent cohorts (n = 3311 PREVEND, TRAILS-CC
and NTR). Imputation quality was very high for NTR (all 25
SNPs: info score .0.72; 21 SNPs: info score .0.90) and TRAIL

PLOS ONE | www.plosone.org

Discovery stage

6

November 2014 | Volume 9 | Issue 11 | e112476

Genes for Heart Rate Variability

S-CC (all 25 SNPs: info score .0.78; 24 SNPs: info score .0.94)
and somewhat lower for PREVEND, which had 18 SNPs of high
quality imputation (r2.0.73), but 7 SNPs with lower imputation
quality (r2,0.35). For one of these SNPs (rs333214 in the SLC5A7
gene) data had to be excluded from the PREVEND cohort as the
imputation quality was too low (r2,0.10) resulting in lower
replication sample size (n = 516). None of the SNPs were
replicated with a nominal p,0.05, except for one SNP. However,
this SNP (rs3731683) showed an effect in the opposite direction as
observed in the discovery stage (see the opposite beta coefficients
for this SNP in Table 3). Thus, none of the SNPs were replicated.
The overall meta-analysis combining discovery and replication
stage (n = 6740) gave no significant Bonferroni corrected (p,
0.0005, conservatively assuming 100 tests for the almost 100
independent tagging SNPs from Table 1) findings for any of the 25
SNPs (Table 3).

replicate the initially discovered associations in independent
samples. As replication failed, our initial findings should be
labeled as false-positive findings, reinforcing the idea that
independent replication is essential in candidate gene studies.
Our two stage association study with large combined sample size
of n = 6740 had more than 80% power with a Bonferroni
corrected alpha of 0.0005 for 100 tests to detect SNPs explaining
as little as 0.32% of the variance in RMSSD. As such it is highly
unlikely that common SNPs in the investigated genes explain a
considerable part of individual differences in RMSSD in rest.
A potential limitation of our study is that the RMSSD measures
in the different cohorts were assessed in both sitting and supine
positions, which might have introduced heterogeneity in our
RMSSD data. Using these heterogeneous phenotypes might have
decreased our power to detect associations somewhat. Not all
SNPs were genotyped in our study, which may have limited our
power to find or confirm significant associations. However,
common SNPs in the discovery cohorts were well imputed (info
score .0.5), because we selected tagging SNPs with good coverage
of the genes and used 1000 Genomes imputation in NESDA. For
the replication cohorts the imputation quality was dependent on
the coverage of the GWAS chip and the imputation software used.
Imputation quality was very high for NTR and TRAILS-CC, but
somewhat lower for 7 SNPs in PREVEND reducing the effective
sample size and power for these SNPs. We guarded against
potential biases caused by the imputation process such as inflated
significance, through properly accounting for uncertainty in these
imputed genotypes in our analyses. Furthermore, the findings and
conclusions of the current study are not generalizable to
individuals of non-European descent.
Another, perhaps more compelling, reason for our null-finding
is that our approach was based on currently existing knowledge
about the acetylcholine pathway. Using a hypothesis-driven design
is a strength, but has also clear downsides. First of all, not all
known elements of the acetylcholinergic signaling cascade were
considered. Second, current knowledge about the acetylcholine
pathways may be vastly incomplete. Third, RMSSD is known to
be a complex phenotype influenced by multiple genes [61],
physiological and psychological systems, and their interactions,
many of which may be outside of the acetylcholine pathways.
In conclusion, no common genetic variants for HRV were
identified in the largest and most comprehensive candidate gene
study on the acetylcholine pathway to date. Future gene finding
efforts for RMSSD may want to focus on hypothesis free
approaches such as the genome-wide association study.

Discussion
The current study comprehensively tested the association
between all common (MAF$5%) variants in eight key genes of
the acetylcholine pathway and an established measure of HRV,
the RMSSD, in subjects of European descent. The eight key genes
were carefully selected in this two-stage candidate gene study on
the basis of their involvement in biosynthesis, transport, breakdown, and receptor binding of acetylcholine. However, none of
the common genetic variants in these eight genes of the
acetylcholine pathway were significantly associated with RMSSD.
Neumann and colleagues [13] genotyped a single SNP
(rs333229) in the choline transporter gene SLC5A7 in their study
of 413 individuals of European ancestry (aged 30 to 54 years).
They found an association with the power in the high frequency
(HF) band (HF power of Fourier transformed inter-beat-interval
time series of RR intervals of the ECG, is another measure of
HRV comparable to RMSSD) obtained during five minutes rest:
compared with GG homozygotes, T allele carriers had higher HF
power. In a more recent study on air pollution in 61 glucose
intolerant subjects, T allele carriers of this SNP (rs333229, which
was one of the 139 tested SNPs) had lower SDNN in response to
air pollution [60]. Interestingly, the exact same SNP in SLC5A7
(rs333229) was genotyped in the current study but did not survive
our discovery stage (i.e., was not significantly associated with
RMSSD). As such, the significant results in the above two
underpowered studies should probably be interpreted as chance
findings, because our discovery stage alone (n = 3429) already had
more than eight times the sample size of the largest of those two
previous studies (n = 413).
Our study has a number of strengths compared to previous
candidate gene studies that investigated only a single SNP in a
single gene and/or had (very) small sample sizes. We comprehensively tested 443 genotyped and imputed common SNPs in eight
key genes of the acetylcholine pathway in which our selected
tagging SNPs covered all SNPs with MAF$5% and r2$0.8
ranging from 210 kb upstream to +10 kb downstream of those
genes. Another strong point of our study is that we aimed to
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